The Current Ratio as of November 2024 (TTM) for Ambrx Biopharma Inc. (AMAM) is 12.80

According to Ambrx Biopharma Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 12.80. This represents a change of 22.94% compared to the average of 10.41 of the last 4 quarters.

Ambrx Biopharma Inc. (AMAM) Historical Current Ratio (quarterly & annually)

How has AMAM Current Ratio performed in the past?

The mean historical Current Ratio of Ambrx Biopharma Inc. over the last ten years is 5.22. The current 12.80 Current Ratio has changed 24.44% with respect to the historical average. Over the past ten years (40 quarters), AMAM's Current Ratio was at its highest in in the June 2023 quarter at 13.28. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Ambrx Biopharma Inc. (AMAM) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Ambrx Biopharma Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ambrx Biopharma Inc. (AMAM) Average Current Ratio

How has AMAM Current Ratio performed in the past?

The current Current Ratio of Ambrx Biopharma Inc. (AMAM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Ambrx Biopharma Inc. (AMAM) Current Ratio vs. Peers

How is AMAM’s Current Ratio compared to its peers?

Ambrx Biopharma Inc.’s Current Ratio is greater than Immix Biopharma, Inc. (3.47), greater than CNS Pharmaceuticals, Inc. (1.82), greater than eFFECTOR Therapeutics, Inc. (1.03), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than Sonnet BioTherapeutics Holdings, Inc. (1.65), less than CohBar, Inc. (15.69), greater than Enveric Biosciences, Inc. (5.17), less than Elevation Oncology, Inc. (17.77), greater than Hepion Pharmaceuticals, Inc. (1.30), greater than Zura Bio Limited (10.36), greater than Ocean Biomedical, Inc. (0.03), less than AVROBIO, Inc. (26.17), less than Day One Biopharmaceuticals, Inc. (14.62), greater than Acumen Pharmaceuticals, Inc. (10.43), greater than X4 Pharmaceuticals, Inc. (4.89), greater than Inozyme Pharma, Inc. (7.68), greater than VectivBio Holding AG (9.14),

Build a custom stock screener for Ambrx Biopharma Inc. (AMAM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ambrx Biopharma Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ambrx Biopharma Inc. (AMAM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ambrx Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.